Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...
She names Eli Lilly (LLY) as one other stock that is "treading water" but in a different manner than tech. Eli Lilly could potentially see $150 to $200 more in this stock coming up, Schneider ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback